Cholesterol-lowering medications, like ezetimibe, may cut liver cancer risk by 31%. Discover how this breakthrough could help ...

The liver, serving as the body's natural filtration system, faces significant challenges from alcohol consumption. As this ...

Metabolic dysfunction-associated steatotic liver disease (MASLD), previously called non-alcoholic fatty liver disease, is a ...

Although all patients with NAFLD need aggressive management of cardiovascular risk factors, it is only patients with NASH who need treatment targeted at the liver disease. None of the currently ...

Cirrhosis creates an ideal setting for liver ... run liver-specific blood tests at the same time. Early detection and management can improve your chances of a good outcome if you do get liver ...

Besides weight loss, exercise can aid in reducing liver fat, improving inflammation biomarkers, and enhancing cardiovascular ...

Coronary artery disease (CAD) is common in patients with cirrhosis, but cirrhosis itself is not significantly associated with an increased CAD risk.

Liver cirrhosis is a late-stage liver disease characterized by the gradual replacement of healthy liver tissue with scar tissue. This condition typically results from long-term chronic hepatitis ...

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment ...

Opens in a new tab or window Postmarketing data on obeticholic acid (Ocaliva) identified a risk for serious liver injury in primary biliary cholangitis (PBC) patients without cirrhosis ...

LPCN 1148 is targeted to be a "First in Class" product candidate with a novel mechanism of action for management of cirrhosis. (PRNewsfoto/Lipocine Inc.) "We are excited the FDA has recognized ...